Monoclonal antibodies targeting Candida disrupt biofilms and inhibit growth across global clinical isolates.

species are a major cause of severe fungal infections, particularly in immunocompromised individuals and hospitalized patients. Among these, stands out as an emerging "superbug", responsible for life-threatening bloodstream infections with mortality rates up to 60%. This multidrug-resistant, hospital-acquired pathogen has been declared a serious global health threat, complicating effective treatment and increasing mortality risks. Our research has identified universal monoclonal antibodies (mAbs) targeting cell wall epitopes, which are highly homologous to those in other pathogenic species, including Passive transfer of mAbs-C3.1 (anti-β-1,2-mannotriose) and 9F2 (anti-phosphoglycerate kinase 1)-significantly extended survival and improved fungal clearance in a complement C5-deficient A/J murine model. Additionally, C3.1 and 9F2 mAbs show direct fungicidal effects against isolates, presenting a promising therapeutic option against this critical threat.